Six-minute walk test in pulmonary arterial hypertension.
Six-minute walk test in pulmonary arterial hypertension.
复制标题
DOI：
10.5152/akd.2015.5834
复制
发表时间：
2015-03
影响因子：
1.3
通讯作者：
Küçükoğlu MS
中科院分区：
文献类型：
--
作者：
Demir R;Küçükoğlu MS
运动不耐受是肺动脉高压（PAH）的主要特征。六分钟步行试验（6MWT）和心肺运动试验广泛用于评估PAH患者的运动能力。6分钟步行距离（6MWD）已被指定为PAH的主要临床结局，并已在许多针对PAH新治疗进行的研究中用作主要终点。在临床研究中使用6MWD作为终点具有许多优点。6MWT是一种价格低廉、易于应用且可重复的标准化测试，PAH患者耐受性良好。此外，它是症状改善的有效措施。它与最大心肺运动试验的变量（作为次最大运动能力的测量）和疾病严重程度标志物（如功能分级和肺血流动力学）相关。它与其他侵入性和非侵入性疾病标志物一起广泛用于临床实践，以评估疾病进展和对治疗的反应。此外，它具有预后重要性，是一个很好的预后标志物。另一方面，使用6MWD作为PAH治疗的主要终点存在局限性。它降低了基线时疾病不太严重和6MWD较高的个体的敏感性，降低了仍在接受PAH治疗的患者评估治疗效果的充分性。尽管存在局限性，但6MWD在PAH患者的评价和管理中发挥着关键作用。
Exercise intolerance is the main characteristic of pulmonary arterial hypertension (PAH). The six-minute walk test (6MWT) and cardiopulmonary exercise test are widely used in assessing exercise capacity of PAH patients. Six-minute walk distance (6MWD) has been specified as the main clinical outcome in PAH and has been used as the primary end-point in many studies conducted for new PAH treatments. Using 6MWD as the end-point in clinical studies has many advantages. 6MWT is an inexpensive, easily applicable, and repeatable standardized test that is well-tolerated by PAH patients. Moreover, it is a valid measure of symptomatic improvement. It is correlated with variables of maximal cardiopulmonary exercise test as a measure of submaximal exercise capacity and disease severity markers such as functional class and pulmonary hemodynamics. It is widely used in clinical practice together with other invasive and non-invasive disease markers in assessing disease progression and response to treatment. In addition, it has prognostic importance and is a good prognostic marker. On the other hand, there are limitations to the use of 6MWD as the primary end-point in PAH treatment. It has decreased sensitivity in individuals with less severe disease and high 6MWD at baseline and decreased adequacy in assessing the effects of treatment in patients who are still under PAH treatment. Despite the limitations, 6MWD plays a key role in the evaluation and management of PAH patients.